Access cutting-edge acute myeloid leukemia treatment through this clinical trial at a research site in Fremont. Study-provided care at no cost to qualified participants.
Access acute myeloid leukemia specialists in Fremont at no cost
This study follows strict safety protocols and ethical guidelines
All study-related acute myeloid leukemia treatment provided free
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may
Sponsor: National Cancer Institute (NCI)
Check if you qualify for this acute myeloid leukemia clinical trial in Fremont, CA
If you're searching for acute myeloid leukemia treatment options in Fremont, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Fremont research site is actively enrolling participants for this clinical trial. You'll receive care from experienced acute myeloid leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.